Cart
sales@molnova.com
ElteN378
CAS No. 1421366-99-5
ElteN378( —— )
Catalog No. M28977 CAS No. 1421366-99-5
ElteN378 is a highly potent synthetic inhibitor of FKBP12 with Ki of 0.5 nM, a low atomic weight ligand with affinity comparable to that of the macrolide Rapamycin.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 312 | In Stock |
|
| 5MG | 376 | In Stock |
|
| 10MG | 558 | In Stock |
|
| 25MG | 896 | In Stock |
|
| 50MG | 1190 | In Stock |
|
| 100MG | 1655 | In Stock |
|
| 200MG | 2213 | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameElteN378
-
NoteResearch use only, not for human use.
-
Brief DescriptionElteN378 is a highly potent synthetic inhibitor of FKBP12 with Ki of 0.5 nM, a low atomic weight ligand with affinity comparable to that of the macrolide Rapamycin.
-
DescriptionElteN378 is a highly potent synthetic inhibitor of FKBP12 with Ki of 0.5 nM, a low atomic weight ligand with affinity comparable to that of the macrolide Rapamycin.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayPI3K/Akt/mTOR signaling
-
TargetmTOR
-
RecptorAntioxidant
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1421366-99-5
-
Formula Weight378.46
-
Molecular FormulaC23H26N2O3
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESO=C([C@@H]1N(C(C(C2=CC=CC=C2)=O)=O)CCCC1)NCCCC3=CC=CC=C3
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Flávia Franceli de Brito Passos, et al. Involvement of Cholinergic and Opioid System in γ-Terpinene-Mediated Antinociception. Evid Based Complement Alternat Med. 2015;2015:829414.
molnova catalog
related products
-
PQR-620
PQR-620 (PQR620) is a novel potent and selective, brain penetrant inhibitor of mTORC1/2.
-
SR9011
SR9011 is a REV-ERB agonist (IC50: 790 nM, REV-ERBα; IC50: 560 nM, REV-ERBβ).
-
DMH-25
DMH25 is a novel covalent and potent inhibitor of mTOR and shows in vivo antitumor activity against triple-negative breast cancer cells.In vivo, DHM25 was an efficient inhibitor of growth and metastasis of triple-negative breast cancer cells, paving the way for its clinical application in oncology.
